Mesalamine FDA label update (2026-11-02)

2 min read Nov 10, 2026, 6:11 AM

Medications Mesalamine Aminosalicylates Regulatory Update Adult patients Clinicians Patients On Biologics Ulcerative colitis

Why This Matters

An FDA label update affects prescribing and monitoring practices. Patients taking mesalamine for ulcerative colitis should be aware of recommended renal monitoring and potential serious adverse reactions that may require stopping the drug.

Who Should Pay Attention

Adults with ulcerative colitis taking mesalamine, gastroenterologists and primary care clinicians who manage IBD medications, and pharmacists.

Study Snapshot

Story typeRegulatory

Evidence typeRegulatory update

Study statusHuman prescription drug

Source depthRegulatory record

What To Know

This is a U.S. FDA drug label (full text).

The label restates the indication for mesalamine extended-release capsules for maintenance of remission of ulcerative colitis in adults and emphasizes warnings and precautions, including monitoring renal function before and during therapy, risk of mesalamine-induced acute intolerance syndrome that can mimic a UC flare, hypersensitivity reactions (including

myocarditis and pericarditis), hepatic failure in patients with pre-existing liver disease, severe cutaneous adverse reactions (SJS/TEN/DRESS), photosensitivity, and reports of mesalamine-containing kidney stones that may not be visible on standard radiography or CT.

Practical note: The label advises evaluating renal function at baseline and periodically, discontinuing mesalamine if renal function worsens, stopping the drug if acute intolerance or serious hypersensitivity is suspected, and ensuring adequate fluid intake to reduce nephrolithiasis risk.

It also notes that mesalamine can interfere with certain urinary normetanephrine assays.

Keep In Mind

This is an FDA drug-label (regulatory-record) document, not a clinical study; it summarizes approved indications and safety information. For individual medical decisions, patients should consult their prescribing clinician. The label reflects reported adverse events and monitoring recommendations rather than new trial efficacy results.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source

Regulatory update Evidence type derived from source or registry metadata.

PublicationopenFDA

PublisherU.S. Food and Drug Administration

SponsorAurobindo Pharma Limited

Study typeDrug Label Update

Indexed viaopenFDA

Source typeRegulatory record

PublishedNov 2, 2026, 12:00 AM

Content availableRegulatory record

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.